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Abstract
Aquaporin-9 (AQP9) is a membrane protein channel that is permeable to a range of small solutes, including glycerol, urea
and nucleobases. Expression of AQP9 in normal brain is limited, while widespread AQP9 expression has previously been
reported in human glioblastoma. However, the specific cellular expression of AQP9 in glioblastoma remains unclear. In this
study, we have examined microarrays to corroborate AQP9 mRNA expression in glioma. These analyses suggested that AQP9
mRNA expression in glioblastoma is primarily explained by tumor infiltration with AQP9 expressing leukocytes.
Immunolabeling confirmed that within tumor regions, AQP9 was expressed in CD15+ and Calgranulin B+ leukocytes, but
also in larger cells that morphologically resembled glioma cells. Specificity of immunoreagents was tested in recombinant
cell lines, leukocyte preparations, and sections of normal human brain and liver tissue. Apparent AQP9+ glioma cells were
frequently observed in proximity to blood vessels, where brain tumor stem cells have been observed previously. A fraction
of these larger AQP9 expressing cells co-expressed the differentiated astrocyte marker GFAP. AQP9 expressing glioma cells
were negative for the brain tumor stem cell marker CD15, but were observed in proximity to CD15+ glioma cells. AQP9
expression may therefore require signals of the perivascular tumor environment or alternatively it may be restricted to a
population of glioma stem cell early progenitor cells.
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Introduction
Aquaporin-9 (AQP9) is a member of the major intrinsic protein
family. It was originally identified in an expression screen for a
putative hepatocyte urea channel [1]. Besides urea, AQP9 was
found to be highly permeable to glycerol, adenine and uracil as
well as moderately permeable to lactate and b-hydroxybutyrate in
the same study [1]. We have recently demonstrated the
physiological importance of AQP9 in hepatocyte gluconeogenesis
from glycerol [2]. Besides in hepatocytes, AQP9 expression has
been described in several tissues, including normal brain.
However, the identified locations of AQP9 expression in murine,
rat and primate brain were not entirely consistent between studies:
AQP9 expression was found in mouse brain in astrocytes, in rat
brain tanycytes, ependymal cells, glia limitans and catecholamin-
ergic neurons, as well as in primates in astrocytes and catechol-
aminergic neurons [3–6].
In one study, where knockout mice were used as controls, no
specific expression of AQP9 was found in brain, while the protein
was readily detectable in liver and epididymis [7]. In a later study,
utilizing the same knockout mice, it was concluded that AQP9 is
expressed in murine brain, albeit at low levels in a narrow
population of neurons [8]. While these discrepancies may in part
be explained by species differences, it is not without precedence
that immunolocalization studies describe inconsistent observa-
tions. Saper [9,10] has therefore suggested a reasonable set of
control experiments that should be conducted in such investiga-
tions.
In human glioblastoma, the most common and aggressive type
of brain tumor, widespread and enhanced AQP9 expression,
compared to normal brain, has been described. These tumors
consist of malignant glioma cells, but also of several other cell types
including cells of the immune system. Specific cell types that
express AQP9 were however not distinguished previously [11]. In
support of AQP9 expression in malignant glioma, another group
found positive correlation between enhanced AQP9 expression
and astrocytoma grade in immunoblots of astrocytoma tissue [12].
The aim in the current study was to verify AQP9 expression in
glioblastoma. A rigorous set of control experiments was included.
Furthermore, we wished to identify the cellular expression of
AQP9 in glioblastoma tissue in co-labeling experiments with
antibodies directed to specific cellular markers. We found that
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AQP9 in glioblastoma tissue biopsies is expressed in a subset of
malignant astrocytic cells and in tumor infiltrating CD15+ and
Calgranulin B+ cells, thus identifying these cells as myelomono-
cytic linage cells, including neutrophils, eosinophils, and some
monocytes, but not basophils [13]. We will refer to these cells as
myelomonocytic cells throughout the manuscript.
Results
Previous studies have suggested enhanced AQP9 expression in
high-grade glioma [11,12]. To obtain further evidence for
enhanced AQP9 expression in glioblastoma and to understand a
possible, underlying mechanism, we analyzed publicly available
microarray data sets [14,15] for correlation between AQP9
expression and other transcripts. The results are summarized in
File S1. We found that AQP9 mRNA was co-regulated with several
transcripts encoding components of the innate immune response,
such as complement components and molecules known to mediate
responses to bacterial lipopolysaccharide (LPS). Specifically, AQP9
expression appeared highly correlated with calgranulin A and
calgranulin B expression (other names: MRP8/S100A8 and MRP14/
S100A9, respectively). These mRNAs encode proteins forming
calgranulin A-calgranulin B dimers, which can act as ligands for
the toll-like receptor 4 (TLR4) LPS receptor [16]. Another
transcript with strong correlation to AQP9 expression, CD14
encodes a LPS receptor [17,18] and may act as a co-receptor of
TLR4 [19]. Calgranulin A and calgranulin B are expressed in
monocytes and together account for 40% of the soluble protein in
neutrophils [20]. CD14 is highly expressed in monocytes and
macrophages and at lower amounts in endothelial and epithelial
cells [21–23]. No strong correlation between AQP9 expression and
astrocytic markers such as glial fibrillary acidic protein (GFAP) and
AQP4 was detected.
In addition, we analyzed AQP9 mRNA expression in the glioma
data set at the ‘‘The Cancer Genome Atlas Network’’ (TCGA,
[24]) website. Patient descriptors with low, average and high
associated AQP9 mRNA expression were retrieved. These patient
descriptors were compared to a recent report by Verhaak et al.
[25], were four types of glioblastoma were distinguished in this
data set. We found that AQP9 expression differed significantly
between glioblastoma types (Figure 1). Out of 26 patients with
elevated AQP9 expression (more than 2-fold above average), 18
patients were afflicted by mesenchymal glioblastoma. High
necrosis and infiltration with inflammatory cells were pointed
out as characteristics of mesenchymal tumors by Verhaak et al.
(2010) [25]. Furthermore, high expression of AQP9 mRNA in
human leukocytes has been described previously [26]. Therefore,
our microarray analyses suggested that previously observed,
enhanced AQP9 mRNA and protein expression in glioblastoma
[12] may be explained by tumor infiltration with AQP9 expressing
leukocytes. Alternatively, AQP9 expression in malignant astrocytic
cells might be correlated with leukocyte infiltration.
To distinguish between these hypotheses we investigated the
cellular expression of AQP9 in formalin fixed paraffin sections of
10 human tumor biopsies that were characterized as glioblastoma
tissue by a pathologist. Initially we sought to establish specificity of
the utilized immunoreagents. Among several tested anti AQP9
sera, we found that a serum raised against a carboxy-terminal
portion of rat AQP9 (RA2674/685) [6] was the most suitable
immunoreagent for our study. Tested antisera and evaluations are
listed in Table 1.
Control experiments included immunofluorescence labeling of
human liver, human leukocytes, normal human brain, and U-87
MG human glioma cells that were transfected to express ectopic
hAQP9. We note that hAQP9 transcript was detected in U-87 MG
cells by PCR above 30 cycles of amplification. No protein could be
detected subsequently by immunofluorescence labeling, as well as
in immunoblots (data not shown). We therefore concluded that
AQP9 mRNA and protein expression in native U-87 MG cells is
very low. In liver, immunoreactivity of anti AQP9 antibody was
detected in hepatocytes (Figure 2A) as previously seen in rodents
and humans [6,7,27]. Control labeling with pre-absorbed anti
AQP9 serum resulted in low background fluorescence (Figure 2B).
Similarly, AQP9 immunoreactivity was not observed in normal
human brain (Figure S1A). U-87 MG cells transiently transfected
with human AQP9-expressing vector showed AQP9 immunore-
activity at the cell periphery (Figure 2C), while there was no
immunolabeling of cells that were transfected with a control vector
(Figure 2D). In the control vector hAQP9 cDNA was inserted in 39
to 59 orientation, i.e. inverted, downstream of the cytomegalovirus
promoter of transcription. Furthermore, we detected AQP9
immunoreactivity in a population of isolated human leukocytes
(Figure 2E), which is in agreement with previous findings, where
AQP9 mRNA was detected in human leukocytes [26,28]. No
unspecific labeling was observed in pre-adsorption controls
(Figure 2F). Double immunolabeling utilizing anti-AQP9 serum
and myelomonocytic markers, anti-CD15, anti-calgranulin A, and
anti-calgranulin B, revealed co-localized immunoractivity (Figure
S1 E–K), indicating that among circulating leukocytes, AQP9 is
expressed in myelomonocytic cells.
In human glioma biopsies we detected a large number of
AQP9+ cells either scattered throughout tumor parenchyma or in
larger clusters that were assessed as immune cells based on cell
size. Further double immunolabeling with anti-AQP9 serum along
with CD15 (Figure 2G) and calgranulin B (Figure 2H), respec-
tively, confirmed that these cells were myelomonocytic cells. These
cells were in part found among erythrocytes, indicating that some
of these cells may stem from hemorrhage. We furthermore
observed myelomonocytic cells in proximity to and within necrotic
tissue areas. Visual impressions of the extent of AQP9 and CD15
immunolabeling are summarized in table 2.
In addition to anti-AQP9 labeling of myelomonocytic cells we
found AQP9 immunoreactivity in cells that morphologically
Figure 1. AQP9 mRNA expression levels in four types of
glioblastoma. Expression levels of AQP9 in 173 patients were
retrieved from the TCGA database and compared to patient descriptors
that have previously been associated with four types of glioblastoma:
classical, mesenchymal, neural and proneural [25]. Chi-square analysis
suggests uneven AQP9 expression levels among these four tumor types
(P,0.0001). High AQP9 expression (.200%) appears to be associated
primarily with mesenchymal tumors. X-axis labels refer to AQP9
expression in specific patients compared to average AQP9 expression
in TCGA glioma samples.
doi:10.1371/journal.pone.0075764.g001
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Table 1. Control experiments performed to assess antigen recognition by antisera and specificity in paraffin embedded tissue
sections.
Antibody Tissue analyzed Result (labeled structures)
anti-AQP9 RA2674/685 human liver hepatocyte basolateral membranes (Figure 2A)
human leukocytes PMNs (Figure 2E)
human brain negative (Figure S1A)
U-87 MG-AQP9 a subset of cells (Figure 2C)
U-87 MG negative (Figure 2D)
anti-AQP9 RA2674/685, blocked human liver negative (Figure 2B)
human leukocytes Negative (Figure 2F)
anti-AQP9 AD U87 MG-AQP9 negative (not shown)
U-87 MG negative (not shown)
anti-AQP9 SC F-17 U87 MG-AQP9 negative (not shown)
U-87 MG negative (not shown)
anti-AQP9 SC C-18 U87 MG-AQP9 a subset of cells (not shown)
U-87 MG negative (not shown
anti-GFAP human brain astrocytes (Figure S1B)
anti-CD133 (3 antibodies) human kidney negative (not shown)
human placenta negative (not shown)
human glioblastoma negative (not shown)
anti-nestin human glioblastoma glioma cells (Figure S1C)
anti-CD31 human liver endothelial cells (Figure S1D)
anti-CD15 human leukocytes PMNs (Figure S1 E and H)
anti-calgranulin A human leukocytes PMNs (Figure S1F)
anti-calgranulin B human leukocytes PMNs (Figure S1 G and H)
doi:10.1371/journal.pone.0075764.t001
Figure 2. Immunofluorescence labeling of human tissue sections. All sections were labeled with anti-AQP9 RA2674/685 serum (green). A:
Liver, B: liver, after AQP9 antibody pre-absorption with immunizing peptide. Labeling of paraffin embedded U-87 MG cells transfected with pIRES-
hAQP9 (C) and pIRES-hAQP9-inverted (D) vectors, respectively. (E) Human leukocytes and (F) leukocytes after pre-absorption with immunizing peptide.
AQP9 immunoreactivity was observed in a subset of leukocytes that were judged to be primarily granulocytes based on their nuclear shape (inset).
(G) Double immunolabeling of AQP9 (green) and CD15 (red) identifying myelomonocytic infiltration in glioblastoma tissue. Cells were labeled by anti-
AQP9 and the anti-CD15 myelomonocytic marker (red). (H) Double immunolabeling utilizing anti-AQP9 and anti-calgranulin B (red) identifies
myelomonocytic cells in glioblastoma tissue. Scale bars: A–H: 50 mm, inset length E and G: 30 mm.
doi:10.1371/journal.pone.0075764.g002
Immunolocalization of AQP9 in Glioblastoma
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resembled astrocytic tumor cells. These cells were typically larger
(16.663.1 SD mm apparent diameter on sections) than AQP9-
positive myelomonocytic cells (10.963.0 SD mm apparent
diameter on sections). Such cells were observed in 7 out of 10
patient biopsies analyzed. Antibodies directed to GFAP are
frequently used in the diagnosis of astrocytic tumors. Consistent
with expectations, GFAP was widely expressed in the studied tissue
sections, while it was lost in some areas [29,30]. Double
immunolabeling, utilizing anti-GFAP and anti-AQP9 sera, showed
that some AQP9-positive cells co-expressed GFAP (Figure 3A–D)
thus identifying these cells as astrocytic cells. The fraction of AQP9
and GFAP double-labeled cells varied between patients. A semi-
quantification of apparent co-localization is given in Table 2. We
note that GFAP expression frequently appears weak in AQP9
expressing cells. Furthermore, we semi-quantified the level of
another related water channel, AQP4 in the investigated biopsies
and found widespread expression in all patient biopsies analyzed
for this marker (Figure S1L). AQP4 expression was observed in
50–100% of glioma cells (Table 2).
We found that larger AQP9 expressing cells were not uniformly
present throughout tumor biopsies. In several places, these AQP9+
cells were apparently localized close to blood vessels. AQP9
immunoreactivity around blood vessels was confirmed in co-
labeling experiments with anti-AQP9 and anti-CD31 sera
(Figure 3E–G). CD31 is specifically expressed in endothelial cells
[31]. No overlap between AQP9 and CD31 immunoreactivity was
observed, indicating absence of AQP9 from endothelial cells. In
addition, we found aggregates of larger AQP9 positive cells in
regions without visible blood vessels (Figure 3H). Due to the
sometimes moderate quality and limited amounts of available
tissue, we cannot exclude that blood supply was present in the
vicinity of these clusters or in nearby sections.
It has been demonstrated that the perivascular environment
harbors and maintains a pool of brain tumor stem cells (BTSC)
[32]. We therefore reasoned that perivascular AQP9 expressing
cells may include BTSCs. In order to test this hypothesis we
performed immunolabeling with previously used BTSC markers
[33,34]. Unfortunately, we were not able to obtain satisfactory
positive control immunolabeling with available antibodies against
CD133 on paraffin embedded human kidney tissue, human
placenta, and human glioblastoma tissue (data not shown). In
contrast, anti-nestin labeling resulted in widespread immunoreac-
tivity in most tumor areas (Figure S1C). Therefore, in agreement
with several previous studies [35–37], we concluded that nestin is
not a selective marker of BTSCs but is also expressed in a large
number of progenitor cells. Furthermore CD15 has been identified
as a marker of BTSCs [38,39]. In addition to robust CD15
immunolabeling of myelomonocytic cells, we observed clear but
weaker immunolabeling of larger cells in sections obtained from
one patient biopsy. Very faint, CD15 immunolabeling of similar
cells was also present in sections obtained from three other
biopsies. No clear overlap between CD15 and AQP9 immunola-
beling was observed in these cells. However, AQP9+ cells were
located in proximity to CD15+ cells (Figure 4).
Discussion
Here we describe a detailed immunolocalization of AQP9 in
human glioblastoma, along with specific cellular markers. In
contrast to a previous study [11], we did not observe ubiquitous
expression of AQP9 in glioblastoma biopsies. We found however
that in some patient-biopsies anti-AQP9 immunolabling was
associated with a large number of myelomonocytic cells. AQP9
immunolabeling was also detected in myelomonocytic cells
isolated from a healthy human donor. This finding is in line with
previous studies where AQP9 mRNA was identified in human
leukocytes [26,28] and AQP9 protein in rat leukocytes [6].
Furthermore, expression of AQP9 in myelomonocytic cells is
Figure 3. Immunofluorescence labeling of human glioblastoma tissue sections. A–D: Double immunofluorescence labeling utilizing anti-
AQP9 RA2674/685 (green) and anti-GFAP sera (red). Partial overlap between AQP9 and GFAP immunolabeling was observed in apparent astrocytic
cells. E–H: Double immunofluorescence labeling utilizing anti-AQP9 and anti-CD31 (red) sera. AQP9 immunoreactivity is localized at the periphery of
malignant cells, which is consistent with expected plasma membrane labeling of this channel protein (E inset). In many places AQP9-postitive tumor
cells are localized near blood vessels (E–G). However, some clusters of AQP9-positivie cells were found without obvious proximity to blood vessel (H).
Scale bars: A–C: 50 mm, D: 25 mm, E–H: 100 mm, inset width E: 120 mm.
doi:10.1371/journal.pone.0075764.g003
Immunolocalization of AQP9 in Glioblastoma
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consistent with our microarray data analysis where we observed a
significant correlation between expression of AQP9 and transcripts
that are typically expressed in leukocytes. Particularly, we detected
high correlation between AQP9, calgranulin A and calgranulin B
expression. Calgranulins A and B encode for proteins that account
for 40% of the soluble proteins in neutrophils. This correlation at
the transcript level was confirmed by co-immunolocalization of
calgranulin B and AQP9 in tumor-associated myelomonocytic
cells, which include neutrophils. We also found that high levels of
AQP9 mRNA expression were correlated with the mesenchymal
type of glioblastoma [25]. This type of glioblastoma is associated
with poor prognosis and high levels of inflammatory infiltrates
[40]. Correlation of AQP9 mRNA expression with the mesenchy-
mal type of glioblastoma therefore appears to result at least in part
from the correlation of mesenchymal glioblastoma with inflam-
matory infiltrates. Furthermore, we found that AQP9 is expressed
in a subset of larger cells that in part co-express GFAP. We
interpret these cells as malignant astrocytic cells. Compared to the
number of myelomonocytic cells in biopsy tissue, the number of
these apparent astrocytic AQP9 expressing cells was limited. We
therefore expect that the influence of these cells on overall
transcript levels in microarray studies is equally small. Further-
more this means that AQP9 expression in astrocytic glioma cells,
as observed in 7 out of 10 evaluated patient biopsies, may not be
correlated with the mesenchymal type of glioblastoma.
Interestingly, in several places AQP9 expressing glioma cells
were localized in close proximity to blood vessels. A perivascular
niche that maintains brain tumor cells in a self-renewing state, so
called brain tumor stem cells (BTSC) has been described
previously [32,41]. In a recent study AQP9 expression has been
described in human glioma derived neurospheres [42], which
suggested AQP9 expression in BTSCs. Widely used BTSC
markers were in our hands not applicable: While we were unable
to detect the CD133 antigen in paraffin embedded tissue sections,
immunolabeling using an antibody directed to nestin resulted in
widespread tumor cell immunoreactivity. The latter was not in
agreement with the idea that nestin could be used as a marker for
BTSCs. It has been reported recently, that CD133 is only
expressed in a subset of glioblastomas [43], while observation of
abundant nestin expression is in complete agreement with several
previous reports that came to the same conclusion [35–37].
Furthermore, specific CD15 immunoreactivity on BTSCs has
been described by several groups [38,39,44,45]. We did observe a
small number of apparent CD15+ cells that were judged to be
astrocytic glioma cells, based on size. We did not observe co-
expression of AQP9 and CD15 in these cells. However, CD15+
cells were observed next to AQP9+ cells. The number of patients
and observed CD15+ cells analyzed in this study was however too
small to draw general conclusions based on these observations.
Furthermore CD15+ BTSCs are not present in every glioblastoma
brain tumor and no single marker protein is currently known that
can conclusively be linked to a glioblastoma stem cell phenotype
[46].
Conclusions
Our studies identify AQP9 expression in a limited population of
glioma cells as well as in tumor infiltrating myelomonocytic cells.
AQP9 expression within tumor parenchyma is not widespread,
compared to abundant expression of the related water channel
AQP4. Consequently, we reason that a major effect of AQP9
expression on tumor associated edema is unlikely. AQP9
expression in astrocytic cells near blood vessels suggests a
connection to signals of the perivascular environment. Alterna-
tively, these cells may represent a population of early glioma stem
cell progenitor cells, based on observed proximity to CD15+ cells.
A putative role of AQP9 in myelomonocytic cells in general as well
as with regard to glioblastoma remains to be determined.
Materials and Methods
Analysis of microarray data
Microarray data sets E-MEXP-567 (16 patients) and E-GEOD-
4290 (178 patients) were downloaded at the EBI website (http://
www.ebi.ac.uk/), imported into Microsoft Excel and the data
headers were edited to fit the Clustal 3.0 input format. Clustal [47]
version 3.0 was downloaded at http://bonsai.hgc.jp/˜mdehoon/
software/cluster/. Treeview was downloaded at http://jtreeview.
sourceforge.net. E-MEXP-567 data were filtered in the software so
that only genes with an expression value of 10 in at least 10
samples were considered (15677 probe sets out of 21587 fit the
criteria). The same list of 15677 probes was selected with the help
of a macro in Microsoft Excel before a separate analysis of the E-
GEOD-4290 data set. Genes were normalized and centered to the
Figure 4. Double-immunofluorescence labeling of human glioma tissue. Robust anti-CD15 (red) and anti-AQP9 co-labeling was observed in
myelomonocytic cells (asterisk). In 4 patient-biopsies weaker CD15 immunolabeling was also observed in a number of larger cells, likely identifying
these cells as BTSCs (examples marked by arrowheads). Non-myelomonocytic AQP9 positive cells (examples marked by arrows) were located near
putative BTSCs, but no clear examples of AQP9 and CD15 co-expression were observed in these cells. Two areas are shown as overlay images (left),
green channel (center) and red channel (right). Nuclei (blue). Scale bar = 20 mm.
doi:10.1371/journal.pone.0075764.g004
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median, before performing complete linkage hierarchical cluster-
ing. The resulting files were imported into Java TreeView and
clades containing AQP9 and related probe expression values were
exported as a text files. After calculation of Pearson correlation
coefficients of expression similarity between AQP9 and related
probe sets, utilizing Graphpad Prism 5 software, genes corre-
sponding to these probe lists were retrieved and analyzed utilizing
DAVID [48,49]. The top ranked genes in both lists appeared
similar. A more detailed analysis was conducted for the E-GEOD-
4290 data set, which is summarized in Spreadsheet S1. Probe to
transcript specificity was analyzed with the help of the AffyPro-
beMiner software [50].
Tissue preparations
Approval to utilize previously established brain tumor biopsies
in this study was obtained from The Central Denmark Region
Committee on Health Research Ethics. Tissue was obtained
during autopsy. Informed consent was therefore not required
under Danish legislation. Data were analyzed anonymously.
Human leukocytes were isolated from a blood sample of the
senior author (MR), with written informed consent. All tissues
were fixed in 10% neutral buffered formalin and sectioned
subsequent to paraffin embedding. Some sections were stained
with hematoxylin and eosin for tumor grading by a pathologist.
Human leukocytes were isolated by a dextran sedimentation
method [51]. A partially purified leukocyte pellet was fixed with
10% neutral buffered formalin for 16 hours, dehydrated and
processed for paraffin embedding.
U-87 MG human glioblastoma cells
Human AQP9 was amplified from cDNA derived from U-87
MG cells utilizing the following oligonucleotides: KpnhAQP9F 59-
AAAGGTACCGTCCTCAGAGAAGCCCCAAG-39 and
NothAQP9R 59- AAAGCGGCCGCTGACTGCAAATCCA-
GAGCTGA-39. The reaction product was inserted into the
PCRII-TOPO vector (Invitrogen), sequenced, liberated with
EcoRI and re-ligated with EcoRI digested pIres2-DsRed2 vector
(Clontech). Plasmid Vectors containing AQP9 in 59-39 (pIRES-
hAQP9) as well as 39-59 (pIRES-hAQP9-inverted) orientation,
respectively, were isolated. U-87 MG cells (LGC standards) were
cultured under standard conditions and transfected with hAQP9
vectors, utilizing Lipofectamin 2000 (Invitrogen) according to the
manufacturer’s specifications. Cells were harvested after they
reached confluency, washed in phosphate buffered saline (PBS),
centrifuged and fixed in 10% buffered formalin for 16 hours,
before paraffin embedding.
Antibodies
Rabbit anti-rat AQP9 serum (RA2674/685) was raised against
a peptide corresponding to amino acids 274–295 and has been
described previously [6]. The following commercially available
antibodies were used in this study: rabbit polyclonal anti-rat AQP9
(Alpha Diagnostic #AQP91-A); goat polyclonal anti-human
AQP9 (F-17, Santa Cruz #sc-14988); goat polyclonal anti-human
AQP9 (C-18, Santa Cruz #sc-14989); monoclonal mouse anti-
CD31 (clone: JC70A; Dako #M0823; 1:25); mouse monoclonal
anti-CD15 raised against purified neutrophils of human origin
(clone: C3D-1; Santa Cruz #sc-19648; 1:25); goat polyclonal anti-
Calgranulin A raised against a peptide mapping at the C-terminus
of human origin (C-19; Santa Cruz #sc-8112; 1:300); goat
polyclonal anti-Calgranulin B raised against a peptide mapping
near the C-terminus of Calgranulin B of human origin (C-19;
Santa Cruz #sc-8114; 1:600); goat polyclonal anti-GFAP raised
against a peptide mapping at the C-terminus of GFAP of human
origin (C-19; Santa Cruz #sc-6170; 1:50); goat polyclonal anti-
CD133 raised against a peptide mapping at the C-terminus of
CD133 of human origin (C-19; Santa Cruz #sc-19365); mouse
monoclonal anti-CD133/1 (clone AC133; Miltenyi Biotec #130-
090-422); mouse monoclonal anti-CD133/2 (clone 293C3;
Miltenyi Biotec #130-090-851); mouse monoclonal anti-Nestin
(clone 10C2; Millipore #MAB5326; 1:1600). Secondary antibod-
ies: donkey anti-mouse Alexa 555 conjugated; donkey anti-goat
Alexa 546 conjugated (Invitrogen) and Donkey anti-rabbit HRP
conjugated (Pierce).
Immunofluorescence
Sections were rehydrated in a series of alcohols (99%, 96%,
70%) for 1 hour, blocked for endogenous peroxides with 3.5%
H2O2 in methanol. Microwave target retrieval treatment was
performed with Retrievit TM Target Retrieval Solution pH10
(BioGenex) according to the manufacturer’s protocol. Human and
mouse tissue sections were blocked with 5% normal human serum
and 5% mouse normal serum, respectively. Primary antibodies
were diluted in PBS containing 0.3% Triton X 100 (PBST) and
1% serum and incubated with sections for 1 hour at RT, followed
by incubation at 4uC overnight. Before incubation with secondary
antibodies, sections were washed in 0.1% PBST and blocked with
5% Normal Donkey Serum (NDS). Secondary antibodies and the
nuclear counter stain (ToPro, Molecular Probes) were diluted
1:1000 in 0.3% PBST, 1% NDS and incubated for 1 hour at room
temperature with the sections. Tyramide Signal Amplification
(TSA) Plus biotin kit (PerkinElmer) was used along with anti-
AQP9 (RA2674/685) antibody. Sections were mounted in glycerol
mounting medium (Dako) including DABCO (1, 4-Diazabicy-
clo[2.2.2]octane; Merck Eurolab A/S). Images were acquired on a
Leica TCS-SP2 confocal microscope (Heidelberg, Germany).
Fluorescence signals were captured within the dynamic range of
signal intensity. Images presented in Figure 4 were captured on a
Zeiss Axioplan 2 microscope equipped for epifluorescence imaging
(Zeiss, Germany) and processed with AxioVision 4.8 software.
Images were assembled in Adobe Photoshop 12.0, without
adjustments in contrast.
Statistical analyses
Chi-square analysis was conducted in Graphpad Prism 5.
Supporting Information
Figure S1 Immunofluorescence labeling of paraffin embedded
tissues. In normal human brain, no immunoreactivity of anti-
AQP9 (green) was detected (A) and anti-GFAP (red) antibody
labeled cells with astrocytic morphology (B). In human glioblas-
toma tissue, anti-nestin (red) labeling was detected in a large
number of glioma cells (C). In human liver, anti-CD31 labeling
(red) was restricted to endothelial cells, as judged by morphological
appearance (D). E–K: immunofluorescence labeling of normal
human leukocytes. E–G and I–K as corresponding magnifications
of above panels: Immunoreactivity of anti-AQP9 (green) co-
localized with anti-CD15 (E and I), calgranulin A (F and J),
calgranulin B (G and K) (all in red) in myelomonocytic cells. H:
immunoreactivity of Calgranulin B (green) co-localized with anti
CD15 (red). L: AQP4 immunoreactivity (red). Scale bar: A–H, L
50 mm, I–K 10 mm, inset width D 30 mm.
(TIF)
File S1 Analysis of publicly available microarray data sets for
correlation between AQP9 expression and other transcripts. AQP9
mRNA was co-regulated with several transcripts (ranked by
Pearson r) encoding components of the innate immune response,
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such as complement components and molecules known to mediate
responses to bacterial lipopolysaccharide (LPS). Specifically, AQP9
expression appeared highly correlated with calgranulin A (S100A8)
and calgranulin B (S100A9).
(XLSX)
Acknowledgments
We acknowledge Professor Mark West for scientific discussions and Inger
Merete Paulsen for technical assistance. Furthermore, Professor Jens
Christian H Sørensen’s help in obtaining paraffin embedded tissue biopsy
material is acknowledged.
Author Contributions
Conceived and designed the experiments: SJ BPU AL JF SN MR.
Performed the experiments: SJ MR. Analyzed the data: SJ BPU MR.
Contributed reagents/materials/analysis tools: BPU SN MR. Wrote the
paper: SJ BPU AL JF SN MR.
References
1. Tsukaguchi H, Shayakul C, Berger UV, Mackenzie B, Devidas S, et al. (1998)
Molecular characterization of a broad selectivity neutral solute channel. J Biol
Chem 273: 24737–24743.
2. Jelen S, Wacker S, Aponte-Santamaria C, Skott M, Rojek A, et al. (2011)
Aquaporin-9 protein is the primary route of hepatocyte glycerol uptake for
glycerol gluconeogenesis in mice. J Biol Chem 286: 44319–44325.
3. Arcienega, II, Brunet JF, Bloch J, Badaut J (2010) Cell locations for AQP1,
AQP4 and 9 in the non-human primate brain. Neuroscience 167: 1103–1114.
4. Badaut J, Hirt L, Granziera C, Bogousslavsky J, Magistretti PJ, et al. (2001)
Astrocyte-specific expression of aquaporin-9 in mouse brain is increased after
transient focal cerebral ischemia. J Cereb Blood Flow Metab 21: 477–482.
5. Badaut J, Petit JM, Brunet JF, Magistretti PJ, Charriaut-Marlangue C, et al.
(2004) Distribution of Aquaporin 9 in the adult rat brain: preferential expression
in catecholaminergic neurons and in glial cells. Neuroscience 128: 27–38.
6. Elkjaer M, Vajda Z, Nejsum LN, Kwon T, Jensen UB, et al. (2000)
Immunolocalization of AQP9 in liver, epididymis, testis, spleen, and brain.
Biochem Biophys Res Commun 276: 1118–1128.
7. Rojek AM, Skowronski MT, Fuchtbauer EM, Fuchtbauer AC, Fenton RA, et al.
(2007) Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice.
Proc Natl Acad Sci U S A 104: 3609–3614.
8. Mylonakou MN, Petersen PH, Rinvik E, Rojek A, Valdimarsdottir E, et al.
(2009) Analysis of mice with targeted deletion of AQP9 gene provides conclusive
evidence for expression of AQP9 in neurons. J Neurosci Res 87: 1310–1322.
9. Saper CB (2005) An open letter to our readers on the use of antibodies. J Comp
Neurol 493: 477–478.
10. Saper CB, Sawchenko PE (2003) Magic peptides, magic antibodies: guidelines
for appropriate controls for immunohistochemistry. J Comp Neurol 465: 161–
163.
11. Warth A, Mittelbronn M, Hulper P, Erdlenbruch B, Wolburg H (2007)
Expression of the water channel protein aquaporin-9 in malignant brain tumors.
Appl Immunohistochem Mol Morphol 15: 193–198.
12. Tan G, Sun SQ, Yuan DL (2008) Expression of the water channel protein
aquaporin-9 in human astrocytic tumours: correlation with pathological grade.
J Int Med Res 36: 777–782.
13. National Library of Medicine. Available: http://www.nlm.nih.gov/mesh/
MBrowser.html Accessed: 2013 August 28.
14. Margareto J, Leis O, Larrarte E, Idoate MA, Carrasco A, et al. (2007) Gene
expression profiling of human gliomas reveals differences between GBM and
LGA related to energy metabolism and notch signaling pathways. J Mol
Neurosci 32: 53–63.
15. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, et al. (2006) High-
resolution global genomic survey of 178 gliomas reveals novel regions of copy
number alteration and allelic imbalances. Cancer Res 66: 9428–9436.
16. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, et al. (2007) Mrp8 and
Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal,
endotoxin-induced shock. Nat Med 13: 1042–1049.
17. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a
receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.
Science 249: 1431–1433.
18. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, et al. (1992) Soluble CD14
participates in the response of cells to lipopolysaccharide. J Exp Med 176: 1665–
1671.
19. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like
receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol
Chem 274: 10689–10692.
20. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N (1991) Identification
of p8,14 as a highly abundant heterodimeric calcium binding protein complex of
myeloid cells. The Journal of biological chemistry 266: 7706–7713.
21. Griffin J, Ritz J, Nadler L, Schlossman S (1981) Expression of myeloid
differentiation antigens on normal and malignant myeloid cells. The Journal of
clinical investigation 68: 932–941.
22. Fearns C, Kravchenko VV, Ulevitch RJ, Loskutoff DJ (1995) Murine CD14
gene expression in vivo: extramyeloid synthesis and regulation by lipopolysac-
charide. J Exp Med 181: 857–866.
23. Jersmann H, Hii C, Hodge G, Ferrante A (2001) Synthesis and surface
expression of CD14 by human endothelial cells. Infection and immunity 69:
479–485.
24. Cancer Genome Atlas Research N (2008) Comprehensive genomic character-
ization defines human glioblastoma genes and core pathways. Nature 455:
1061–1068.
25. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated
genomic analysis identifies clinically relevant subtypes of glioblastoma charac-
terized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:
98–110.
26. Tsukaguchi H, Weremowicz S, Morton CC, Hediger MA (1999) Functional and
molecular characterization of the human neutral solute channel aquaporin-9.
Am J Physiol 277: F685–696.
27. Rodriguez A, Catalan V, Gomez-Ambrosi J, Garcia-Navarro S, Rotellar F, et al.
(2011) Insulin- and leptin-mediated control of aquaglyceroporins in human
adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling
cascade. J Clin Endocrinol Metab 96: E586–597.
28. Ishibashi K, Kuwahara M, Gu Y, Tanaka Y, Marumo F, et al. (1998) Cloning
and functional expression of a new aquaporin (AQP9) abundantly expressed in
the peripheral leukocytes permeable to water and urea, but not to glycerol.
Biochem Biophys Res Commun 244: 268–274.
29. van der Meulen JD, Houthoff HJ, Ebels EJ (1978) Glial fibrillary acidic protein
in human gliomas. Neuropathol Appl Neurobiol 4: 177–190.
30. Velasco ME, Dahl D, Roessmann U, Gambetti P (1980) Immunohistochemical
localization of glial fibrillary acidic protein in human glial neoplasms. Cancer 45:
484–494.
31. Newman PJ, Berndt MC, Gorski J, White GC 2nd, Lyman S, et al. (1990)
PECAM-1 (CD31) cloning and relation to adhesion molecules of the
immunoglobulin gene superfamily. Science 247: 1219–1222.
32. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. (2007) A
perivascular niche for brain tumor stem cells. Cancer Cell 11: 69–82.
33. Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, et al. (2007)
CD133 is not present on neurogenic astrocytes in the adult subventricular zone,
but on embryonic neural stem cells, ependymal cells, and glioblastoma cells.
Cancer Res 67: 5727–5736.
34. Aguado T, Carracedo A, Julien B, Velasco G, Milman G, et al. (2007)
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagen-
esis. J Biol Chem 282: 6854–6862.
35. Sugawara K, Kurihara H, Negishi M, Saito N, Nakazato Y, et al. (2002) Nestin
as a marker for proliferative endothelium in gliomas. Lab Invest 82: 345–351.
36. Shervington A, Lu C (2008) Expression of multidrug resistance genes in normal
and cancer stem cells. Cancer Invest 26: 535–542.
37. Kitai R, Horita R, Sato K, Yoshida K, Arishima H, et al. (2010) Nestin
expression in astrocytic tumors delineates tumor infiltration. Brain Tumor
Pathol 27: 17–21.
38. Mao XG, Zhang X, Xue XY, Guo G, Wang P, et al. (2009) Brain Tumor Stem-
Like Cells Identified by Neural Stem Cell Marker CD15. Transl Oncol 2: 247–
257.
39. Son MJ, Woolard K, Nam DH, Lee J, Fine HA (2009) SSEA-1 is an enrichment
marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4: 440–
452.
40. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern
of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157–
173.
41. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, et al. (2010)
Perivascular nitric oxide activates notch signaling and promotes stem-like
character in PDGF-induced glioma cells. Cell Stem Cell 6: 141–152.
42. Fossdal G, Vik-Mo EO, Sandberg C, Varghese M, Kaarbo M, et al. (2012) Aqp
9 and brain tumour stem cells. ScientificWorldJournal 2012: 915176.
43. Schittenhelm J, Simon P, Harter PN, Zachskorn C, Schlaszus H, et al. (2011)
CD133 expression is associated with small round blue cell tumour morphology
in human central nervous system neoplasms. Histopathology 58: 739–749.
44. Ward RJ, Lee L, Graham K, Satkunendran T, Yoshikawa K, et al. (2009)
Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medullo-
blastoma. Cancer Res 69: 4682–4690.
45. Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, et al. (2009)
Identification of CD15 as a marker for tumor-propagating cells in a mouse
model of medulloblastoma. Cancer Cell 15: 135–147.
46. Brescia P, Richichi C, Pelicci G (2012) Current strategies for identification of
glioma stem cells: adequate or unsatisfactory? Journal of oncology 2012: 376894.
Immunolocalization of AQP9 in Glioblastoma
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e75764
47. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:
14863–14868.
48. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
49. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
4: 3.
50. Liu H, Zeeberg BR, Qu G, Koru AG, Ferrucci A, et al. (2007) AffyProbeMiner:
a web resource for computing or retrieving accurately redefined Affymetrix
probe sets. Bioinformatics 23: 2385–2390.
51. Nauseef WM (2007) Isolation of human neutrophils from venous blood.
Methods Mol Biol 412: 15–20.
Immunolocalization of AQP9 in Glioblastoma
PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e75764
